Changes in plasma cardiac natriuretic peptides concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy
- PMID: 9021441
Changes in plasma cardiac natriuretic peptides concentrations during 1 year treatment with angiotensin-converting enzyme inhibitor in elderly hypertensive patients with left ventricular hypertrophy
Abstract
Plasma concentrations of atrial and brain natriuretic peptides (ANP and BNP) are high in patients with hypertension and congestive heart failure. The present study examined changes in plasma ANP and BNP concentrations during 1 year of monotherapy with enalapril in elderly hypertensive patients with left ventricular (LV) hypertrophy. Eight elderly hypertensive patients with LV hypertrophy were treated with enalapril for 1 year, during which time serial changes were recorded in LV mass index, LV systolic function, and plasma concentrations of ANP and BNP. Enalapril maintained systolic and diastolic blood pressure in the normal range for over 1 year. Treatment significantly reduced posterior wall thickness at 6 months, and more so at 1 year, and tended to reduce septal wall thickness and LV mass index at 1 year. LV ejection fraction was slightly but significantly increased at 1 year. Plasma ANP and BNP, which were markedly elevated at study entry, both decreased after 1 year of enalapril. These results suggest that 1 year of treatment with enalapril caused both a modest regression of LV hypertrophy and a modest improvement in LV systolic function in our selected group of elderly hypertensive patients. The drug reduced elevated plasma ANP and BNP levels but did not alter BUN and serum creatinine levels. Enalapril appears to be useful for the treatment of elderly hypertensive patients with LV hypertrophy.
Similar articles
-
Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor.Am J Med. 1995 Mar;98(3):257-65. doi: 10.1016/S0002-9343(99)80372-6. Am J Med. 1995. PMID: 7872342 Clinical Trial.
-
Natriuretic peptides as markers of preclinical cardiac disease in obesity.Eur J Clin Invest. 2004 May;34(5):342-8. doi: 10.1111/j.1365-2362.2004.01348.x. Eur J Clin Invest. 2004. PMID: 15147331
-
Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.Blood Press Suppl. 1995;1:1-45. Blood Press Suppl. 1995. PMID: 7599749 Clinical Trial.
-
Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.Minerva Cardioangiol. 2002 Jun;50(3):169-74. Minerva Cardioangiol. 2002. PMID: 12107398 Review.
-
[Brain natriuretic peptide].Ann Ital Med Int. 1995 Oct-Dec;10(4):233-41. Ann Ital Med Int. 1995. PMID: 8718658 Review. Italian.
Cited by
-
Prevalence and misdiagnosis of chronic heart failure in nursing home residents: the role of B-type natriuretic peptides.Neth Heart J. 2008 Apr;16(4):123-8. doi: 10.1007/BF03086130. Neth Heart J. 2008. PMID: 18427636 Free PMC article.
-
The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill.Transfusion. 2009 Jan;49(1):13-20. doi: 10.1111/j.1537-2995.2008.01941.x. Epub 2008 Oct 14. Transfusion. 2009. PMID: 18954397 Free PMC article.
-
Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP.Heart. 2000 Mar;83(3):278-82. doi: 10.1136/heart.83.3.278. Heart. 2000. PMID: 10677405 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical